{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:12:59Z","timestamp":1792383179803,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Spinal Cord"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1038\/sc.2013.19","type":"journal-article","created":{"date-parts":[[2013,6,7]],"date-time":"2013-06-07T11:04:54Z","timestamp":1370603094000},"page":"432-441","source":"Crossref","is-referenced-by-count":66,"title":["Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics"],"prefix":"10.1038","volume":"51","author":[{"given":"H","family":"Madersbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"M\u00fcrtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"St\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,7]]},"reference":[{"key":"BFsc201319_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"C Chapple","year":"2008","unstructured":"Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D . The effects of antimuscarinic tretaments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543\u2013562.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.eururo.2006.07.017","volume":"50","author":"G Novara","year":"2006","unstructured":"Novara G, Galfano A, Ficarra V, Artibani W . Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006; 50: 675\u2013683.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","volume":"65","author":"SA Kaplan","year":"2011","unstructured":"Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z . Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011; 65: 487\u2013507.","journal-title":"Int J Clin Pract"},{"key":"BFsc201319_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2009.04.028","volume":"56","author":"M St\u00f6hrer","year":"2009","unstructured":"St\u00f6hrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; 56: 81\u201388.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata P, Hasafa Z, Singh M, Abdel-Fattah M . Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 2012; 62: 816\u2013830.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR6","first-page":"A190","volume":"22","author":"J Bycroft","year":"2003","unstructured":"Bycroft J, Leaker B, Wood S, Knight S, Shah G, Craggs M . The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Annual meeting of the International Continence Society, Florence, Italy, 2003. Neurourol Urodyn 2003; 22: A190.","journal-title":"Neurourol Urodyn"},{"key":"BFsc201319_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.urology.2009.05.008","volume":"74","author":"MJ Kennelly","year":"2009","unstructured":"Kennelly MJ, Lemack GE, Foote JE, Trop CS . Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74: 741\u2013745.","journal-title":"Urology"},{"key":"BFsc201319_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0090-4295(99)00540-3","volume":"55","author":"J Pannek","year":"2000","unstructured":"Pannek J, Sommerfeld HJ, B\u00f6tel U, Senge T . Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000; 55: 358\u2013362.","journal-title":"Urology"},{"key":"BFsc201319_CR9","unstructured":"Oxford Centre for Evidence-based Medicine Levels of evidence (May 2011). Produced by Bob Philips, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawessince November 1998."},{"key":"BFsc201319_CR10","first-page":"447","volume":"33","author":"D Mazur","year":"1994","unstructured":"Mazur D, G\u00f6cking K, Wehnert J, Schubert G, Herfurth G, Alken RG . Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence: a multicentre dose-optimizing study. Urologe A 1994; 33: 447\u2013452.","journal-title":"Urologe A"},{"key":"BFsc201319_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","volume":"17","author":"P Van Kerrebroeck","year":"1998","unstructured":"Van Kerrebroeck P, Amarenco G, Th\u00fcroff J, Madersbacher HG, Lock MT, Messelink EJ et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17: 499\u2013512.","journal-title":"Neurourol Urodyn"},{"key":"BFsc201319_CR12","unstructured":"St\u00f6hrer M, Bersch U, G\u00f6cking K, Schurch B, Kramer G . Dose finding study for treatment of detrusor hyperreflexia by trospium chloride. Presented at: Annual Meeting of the International Medical Society of Paraplegia. Iguassu, Brazil 1998."},{"key":"BFsc201319_CR13","unstructured":"St\u00f6hrer M, Frohneberg D, Loechner-Ernst D, Sauter P, Mandaika B . Oxybutynin in the treatment of detrusor hyperreflexia in patients with spinal cord injury: A multicentre randomised double-blind study. Presented at: Annual Meeting of the American Spinal Cord Injury Association. Orlando, USA 1990."},{"key":"BFsc201319_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.sc.3100750","volume":"37","author":"M St\u00f6hrer","year":"1999","unstructured":"St\u00f6hrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K . Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia\u2014a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37: 196\u2013200.","journal-title":"Spinal Cord"},{"key":"BFsc201319_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000282207","volume":"47","author":"M St\u00f6hrer","year":"1991","unstructured":"St\u00f6hrer M, Bauer P, Giannetti BM et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 1991; 47: 138\u2013143.","journal-title":"Urol Int"},{"key":"BFsc201319_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","volume":"27","author":"KD Ethans","year":"2004","unstructured":"Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI . Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27: 214\u2013218.","journal-title":"J Spinal Cord Med"},{"key":"BFsc201319_CR17","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/S1569-9056(12)60464-3","volume":"11","author":"G Amarenco","year":"2012","unstructured":"Amarenco G, Sutory M, Fagertun H, Wright M, Compion G, DeRidder D . Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity. Preliminary results from the SONIC urodynamic study. Eur Urol, Suppl 2012; 11: e467.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","volume":"135","author":"JB Gajewski","year":"1986","unstructured":"Gajewski JB, Awad SA . Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986; 135: 966\u2013968.","journal-title":"J Urol"},{"key":"BFsc201319_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","volume":"75","author":"H Madersbacher","year":"1995","unstructured":"Madersbacher H, St\u00f6hrer M, Richter R, Burgd\u00f6rfer H, Hachen HJ, M\u00fcrtz G . Trospium chloride versus oxybuynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Brit J Urol 1995; 75: 452\u2013456.","journal-title":"Brit J Urol"},{"key":"BFsc201319_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","volume":"51","author":"M St\u00f6hrer","year":"2007","unstructured":"St\u00f6hrer M, M\u00fcrtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ., Propiverine Study Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity\u2014results of a randomized, double blind, multicenter clinical study. Eur Urol 2007; 51: 235\u2013242.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sc.2012.174","volume":"51","author":"M St\u00f6hrer","year":"2013","unstructured":"St\u00f6hrer M, M\u00fcrtz G, Kramer G, Warnack W, Primus G, Jinga V et al. Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity. Spinal Cord 2013; 51: 209\u2013213.","journal-title":"Spinal Cord"},{"key":"BFsc201319_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/01.ju.0000103274.38694.b1","volume":"171","author":"N Bennett","year":"2004","unstructured":"Bennett N, O\u2019Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB . Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171: 749\u2013751.","journal-title":"J Urol"},{"key":"BFsc201319_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/10790268.2003.11753678","volume":"26","author":"M O\u2018Leary","year":"2003","unstructured":"O\u2018Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB . Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26: 159\u2013162.","journal-title":"J Spinal Cord Med"},{"key":"BFsc201319_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.5414\/CPP44623","volume":"44","author":"M Menarini","year":"2006","unstructured":"Menarini M, Del Popolo G, Benedetto D, Haselmann J, B\u00f6deker RH, Schwantes U et al. Trospium chloride in patients with neurogenic detrusor overactivity: Is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44: 623\u2013632.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"BFsc201319_CR25","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1569-9056(12)60466-7","volume":"11","author":"C Persu","year":"2012","unstructured":"Persu C, Gaevlete PA . Double dose of solifenacin for the treatment of neurogenic detrusor overactivity. Eur Urol, Suppl 2012; 11: e469.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/nau.20289","volume":"25","author":"M Horstmann","year":"2006","unstructured":"Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD . Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25: 441\u2013445.","journal-title":"Neurourol Urodyn"},{"key":"BFsc201319_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","volume":"53","author":"B Amend","year":"2008","unstructured":"Amend B, Hennenlotter J, Schaefer T, Horstmann M, Stenzl A, Sievert KD . Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53: 1021\u20131028.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","volume":"182","author":"AP Cameron","year":"2009","unstructured":"Cameron AP, Clemens JQ, Latini JM, McGuire EJ . Combination drug therapy improves compliance of the neurogenic bladder. J Urol 2009; 182: 1062\u20131067.","journal-title":"J Urol"},{"key":"BFsc201319_CR29","first-page":"260","volume":"30","author":"M Madersbacher","year":"1991","unstructured":"Madersbacher M, St\u00f6hrer M, Richter R, Giannetti BM, M\u00fcrtz G . High-dose administration of trospium chloride in the treatment of detrusor hyperreflexia. Urologe 1991; 30: 260\u2013263.","journal-title":"Urologe"},{"key":"BFsc201319_CR30","unstructured":"Geirsson G, Schoefield D, Haughie S, Steihdotsdottir S, Hardardottir A, Glue P et al. Assessment of time to onset: the effect of single oral dose of tolterodine on neurogenic detrusor overactivity in spinal cord injury patients. Presented at: Annual Meeting of the International Continence Society 2006 (Abstract 309)."},{"key":"BFsc201319_CR31","unstructured":"Yamanishi T, Mizuro T, Yoshida K, Uchiyama T, Sakakibara R . Efficacy of tolterodine ER for the treatment of neurogenic detrusor overactivity or low compliance bladder\u2014assessment by urodynamic study. Presented at: Annual Meeting of the International Continence Society 2009 (Abstract 330)."},{"issue":"Suppl","key":"BFsc201319_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.urology.2006.08.736","volume":"68","author":"S Carl","year":"2006","unstructured":"Carl S, Laschke S . Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology 2006; 68 (Suppl): 250.","journal-title":"Urology"},{"key":"BFsc201319_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1569-9056(07)60999-3","volume":"6","author":"M Spinelli","year":"2007","unstructured":"Spinelli M, Citari M, Zanollo L et al. Solifenacin in neurogenic overactive bladder. Eur Urol Suppl 2007; 6: 273.","journal-title":"Eur Urol Suppl"},{"key":"BFsc201319_CR34","doi-asserted-by":"publisher","first-page":"834753","DOI":"10.1155\/2011\/834753","volume":"2011","author":"F van Rey","year":"2011","unstructured":"van Rey F, Heesakkers J . Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011; 2011: 834753.","journal-title":"Adv Urol"},{"key":"BFsc201319_CR35","first-page":"74","volume":"2","author":"D Mazur","year":"1994","unstructured":"Mazur D, G\u00f6cking K, Wehnert J, Dorschner W, Schubert G, HerFurth G et al. Vertr\u00e4glichkeit und Wirksamkeit einer Langzeittherapie mit Propiverinhydrochlorid bei neurogener Hatrninkontinenz. Eine multizentrische Studie. Kontinenz 1994; 2: 74\u201378.","journal-title":"Eine multizentrische Studie. Kontinenz"},{"key":"BFsc201319_CR36","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1016\/S1569-9056(12)60465-5","volume":"11","author":"S Proietti","year":"2012","unstructured":"Proietti S, Lepri E, Lepri L, Lolli C, Gubbiotti M, Giannantoni A . Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by multiple sclerosis: Long term follow up. Eur Urol, Suppl 2012; 11: e468.","journal-title":"Eur Urol"},{"key":"BFsc201319_CR37","doi-asserted-by":"crossref","unstructured":"Tan YK, Toh KL . Tolterodine improves the compliance and cystometric capacity of adult neurogenic bladders secondary to spinal cord injury. Presented at: Annual Meeting of the International Continence Society 2009 (Abstract 331).","DOI":"10.1016\/j.urology.2009.07.631"},{"key":"BFsc201319_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/nau.10099","volume":"22","author":"GA Digesu","year":"2003","unstructured":"Digesu GA, Khullar V, Cardozo L, Salvatore S . Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003; 22: 105\u2013108.","journal-title":"Neurourol Urodyn"},{"key":"BFsc201319_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-5347(17)54449-3","volume":"126","author":"EJ McGuire","year":"1981","unstructured":"McGuire EJ, Woodside JR, Borden TA, Weiss RM . Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126: 205\u2013209.","journal-title":"J Urol"},{"key":"BFsc201319_CR40","doi-asserted-by":"publisher","first-page":"e16718","DOI":"10.1371\/journal.pone.0016718","volume":"6","author":"TM Kessler","year":"2011","unstructured":"Kessler TM, Bachmann LM, Minder C, L\u00f6hrer D, Umbehr M, Sch\u00fcnemann HJ et al. Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic apoproach. PLoS One 2011; 6: e16718.","journal-title":"PLoS One"},{"key":"BFsc201319_CR41","unstructured":"Uchiyama T, Sakakibara R, Liu Z et al. The effects of anticholinergic drugs on cognitive impairment, mental dysfunction and motor dysfunction in patients with neurological disease. 35thAnnual Meeting of the ICS, 28 August-2 September 2005 Montreal, Canada. Conference Proceedings."},{"key":"BFsc201319_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/nau.21129","volume":"30","author":"JJ Wyndaele","year":"2011","unstructured":"Wyndaele JJ, Gammie A, Bruschini H, De Wachter S, Fry CH, Jabr RI et al. Bladder compliance what does it represent: Can we measure it, and is it clinically relevant? Neurourol Urodyn 2011; 30: 714\u2013722.","journal-title":"Neurourol Urodyn"}],"container-title":["Spinal Cord"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/sc201319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sc201319","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sc201319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:24:52Z","timestamp":1684621492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/sc201319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["BFsc201319"],"URL":"https:\/\/doi.org\/10.1038\/sc.2013.19","relation":{},"ISSN":["1362-4393","1476-5624"],"issn-type":[{"value":"1362-4393","type":"print"},{"value":"1476-5624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}